33115 results about "Hydroxy group" patented technology

Disclosed herein is a composition comprising: (A) a lubricant or a hydrocarbon fuel; (B) at least one hydroxy carboxylic acid ester or hydroxy polycarboxylic acid ester having the generic formula defined herein; and (C) at least one phosphorus-containing additive.

The invention provides a lubricating composition containing an oil of lubricating viscosity, an oil soluble molybdenum compound, and an ashless antiwear agent. The invention further provides for a new antioxidant. The lubricating composition is suitable for lubricating an internal combustion engine.

Improved methods for synthesis of oligonucleotides and other phosphorus-linked oligomers are disclosed. The methods include the use of aromatic solvents, alkyl aromatic solvents, halogenated aromatic solvents, halogenated alkyl aromatic solvents, or aromatic ether solvents to achieve deprotection of protected hydroxyl groups.

An acid fracturing method is provided in which the acid is generated in the fracture by hydrolysis of a solid acid-precursor selected from one or more than one of lactide, glycolide, polylactic acid, polyglycolic acid, a copolymer of polylactic acid and polyglycolic acid, a copolymer of glycolic acid with other hydroxy-, carboxylic acid-, or hydroxycarboxylic acid-containing moieties, and a copolymer of lactic acid with other hydroxy-, carboxylic acid or hydroxycarboxylic acid-containing moieties. The solid acid-precursor may be mixed with a solid acid-reactive material to accelerate the hydrolysis and / or coated to slow the hydrolysis. Water-soluble liquid compounds are also given that accelerate the hydrolysis. The method ensures that the acid contacts fracture faces far from the wellbore.

Electroluminescent devices and materials including an electroluminescent organo-siloxane polymer. The main chain of the organo-siloxane polymer comprises an organic component that can be alkenyl, alkynyl, aralkyl, aryl, heteroaralkyl, and heteroaryl which can be substituted optionally with hydrogen, alkyl, aryl, heteroalkyl, heteroaralkyl, nitro, cyano, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, halogen, dialkylamino, diarylamino, diaralkylamino, arylamino, alkylamino, arylalkylamino, carbonyloxy, carbonylalkoxy, carbonylalkyloxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxylcarbonyloxy, sulfonyl, or sulfonyloxy. The organic component includes at least two covalent bonds coupling the organic component to the main chain of the organo-siloxane polymer. Such devices provide superior performance and mechanical stability compared with conventional organic electroluminescent materials and devices made from such materials.

The present invention relates to a cross-linker for photoresist compositions which is suitable for a photolithography process using KrF (248 mn), ArF (193 mn), E-beam, ion beam or EUV light sources. Preferred cross-linkers, according to the present invention, comprise a copolymer of (i) a compound represented by following Chemical Formula 1 and / or (ii) one or more compound(s) selected from the group consisting of acrylic acid, methacrylic acid and maleic anhydride. ##STR1## wherein, R.sub.1 and R.sub.2 individually represent straight or branched C.sub.1-10 alkyl, straight or branched C.sub.1-10 ester, straight or branched C.sub.1-10 ketone, straight or branched C.sub.1-10 carboxylic acid, straight or branched C.sub.1-10 acetal, straight or branched C.sub.1-10 alkyl including at least one hydroxyl group, straight or branched C.sub.1-10 ester including at least one hydroxyl group, straight or branched C.sub.1-10 ketone including at least one hydroxyl group, straight or branched C.sub.1-10 carboxylic acid including at least one hydroxyl group, and straight or branched C.sub.1-10 acetal including at least one hydroxyl group; and R.sub.3 represents hydrogen or methyl.

There is provided a composition for forming an EUV resist overlayer film that is used in an EUV lithography process, that does not intermix with the EUV resist, that blocks unfavorable exposure light for EUV exposure, for example, UV light and DUV light and selectively transmits EUV light alone, and that can be developed with a developer after exposure. A composition for forming an EUV resist overlayer film used in an EUV lithography process including a resin containing a naphthalene ring in a main chain or in a side chain and a solvent, in which the resin may include a hydroxy group, a carboxy group, a sulfo group, or a monovalent organic group having at least one of these groups as a hydrophilic group.

A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof.

The present invention relates to a stress stable lathering skin cleansing liquid composition comprising by weight parts of the liquid composition: (a) from about 0.5 parts to 10 parts of a stabilizer; for example trihydroxystearin; (b) from about 1 part to about 80 parts of lipid skin moisturizing agent; (c) from about 1 part to about 30 parts of surfactant having a combined CMC equilibrium surface tension value of from 15 to 50; (d) water; wherein said stress stable lathering skin cleansing liquid composition has a Lipid Deposition Value (LDV) of from about 5 to about 100 and wherein said composition is stable for at least two weeks at 100 F.

An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1 / Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral diseases and cancers, which is represented by the following formula (1): wherein A is a group of a formula represented by the formula (2): wherein R2 is a substituted or unsubstituted alkyl group and so on, R3 is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0˜2, X1 is oxygen atom, Z is straight or branched chain alkylene, and R1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Stain-removing oral compositions, such as gum compositions are herein provided. The compositions include a chelating agent and a surfactant. The surfactant includes a fatty acid salt and at least one component selected from nonionic and anionic surfactants. The fatty acid salt may have at least one hydroxyl functionality. The oral compositions may optionally include an abrasive agent.

Disclosed is a polycarbonate composition and process from making same, wherein introduction of a chain terminator and an acyl halide other than phosgene is after at least 25 percent of the hydroxyl groups in the dihydric phenol have been converted to chloroformate groups.

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

The present invention provides a composition comprising HMB and at least one amino acid. The present invention also provides a method for the treatment of disease-associated wasting of an animal, a method for decreasing the serum-level of triglycerides of an animal, a method for decreasing the serum viral load of an animal, and a method for redistributing fat in an animal having a visceral region and a subcutaneous region. All methods comprise administering to the animal a composition comprising HMB and at least one amino acid.

The light emitting device of the present invention relates to a light emitting device which is characterized in that it is a device with an emissive substance present between an anode and cathode, and which emits light by means of electrical energy, and said device has a least one type of compound denoted by (a) to (d) below. (a) A compound having a plurality of 1,7-phenanthroline skeletal structures (b) A benzoquinoline derivative (c) A spiro compound represented by general formula (1) A1 and A2 are each selected from single bonds, substituted or unsubstituted alkyl chains, ether chains, thioether chains, ketone chains and substituted or unsubstituted amino chains. However, A1<> A2. Z represents carbon or silicon. R1 to R16 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. (d) A tetraphenylmethane derivative represented by general formula (2) R17 to R36 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. However, at least one of R17 to R36 is selected from substituents represented by general formula (3). -X-Ar (3) X is a single bond or is selected from the following, and Ar denotes a condensed aromatic ring or heteroaromatic ring. In the case where X is phosphorus oxide, then Ar represents an aromatic hydrocarbon or heteroaromatic ring. n is an natural number.

The invention is directed to a process for the preparation of α,β-unsaturated acids, esters and amides from α- or β-hydroxycarboxylic acids or esters or precursors in high yields and high selectivity. The α,β-unsaturated acids or esters are optionally prepared in the presence of specific dehydration and / or esterification catalysts. The α,β-unsaturated amides or substituted amides are prepared optionally in the presence of a dehydration and / or amidation catalyst. The source of α- or β-hydroxycarboxylic acids or precusor is preferably from a renewable resource. The precursor is defined herein.

Described is a method for making a composition comprising alkanes. The composition is suitable for use as a liquid transportation fuel in general, and jet fuel in particular. The method includes dehydrating a feedstock solution comprising a carbohydrate, in the presence of an acid catalyst, to yield at least one furan derivative compound, in a reaction vessel containing a biphasic reaction medium: an aqueous reaction solution and a substantially immiscible organic extraction solution. The furan derivative compound is then subjected to a self-aldol condensation reaction or a crossed-aldol condensation reaction with another carbonyl compound to yield a beta-hydroxy carbonyl compound and / or an alpha-beta unsaturated carbonyl compound. The beta-hydroxy carbonyl and / or alpha-beta unsaturated compounds are then hydrogenated to yield a saturated or partially saturated compound, followed by hydrodeoxygenation (e.g., dehydrating and hydrogenating) of the saturated or partially saturated compound to yield a composition of matter comprising alkanes.

The invention provide a class of chain-extended polysiloxane crosslinkers which comprises (1) at least two polysiloxane segments, wherein each pair of adjacent polysiloxane segments is linked by one divalent organic radical which includes at least one pendant hydrophilic group (hydroxyl and / or carboxyl groups) or at least one dangling hydrophilic polymer chain and a di-thioether linkage —S-DR-S— in which DR is a divalent organic radical; and (2) two terminal ethylenically unsaturated groups. The present invention is also related to a polymer comprising crosslinking units derived from chain-extended polysiloxane crosslinker of the invention and to ophthalmic lenses comprising such a polymer.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

The present invention provides transparent silicone hydrogels with high acrylamide monomer content and an excellent balance between moisture content.The silicone hydrogels may be obtained by polymerizing a monomer mix containing a plurality of monomers, wherein the monomer mix comprises about 30 to about 98% by weight of at least one type of silicone monomer which is, and about 1 to about 50% by weight of at least one type of non-silicone type (meth)acrylamide monomer containing two or more hydroxyl groups within a molecule; wherein the weight percents are based upon the total amount of monomer components and polymer components in the monomer mix.

PCT No. PCT / EP97 / 04908 Sec. 371 Date Mar. 17, 1999 Sec. 102(e) Date Mar. 17, 1999 PCT Filed Sep. 19, 1997 PCT Pub. No. WO98 / 12242 PCT Pub. Date Mar. 20, 1998Biodegradable polyesters based on A) 95-99.99 mol % of at least one polyester A containing as monomeric building blocks of an acid component comprising a11) 20-95 mol % of at least one aliphatic or cycloaliphatic dicarboxylic acid or its ester-forming derivative and a12) 5-80 mol % of at least one aromatic dicarboxylic acid or its ester-forming derivative and at least one dihydroxy compound or at least one amino alcohol or their mixtures, and B) 0.01-5 mol % of a mixture comprising mono-, bi-, tri-, tetra- and higher-nuclear isocyanurates or corresponding compounds containing two, three or four functional groups capable of reacting with the end groups of polyester A, or mixtures of the isocyanurates and the corresponding compounds, as well as molding compositions comprising said polyesters, their manufacture and their use in the manufacture of moldings, filsm, fibers and coatings.

The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2—R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb, SO2NR7R8, CONR7R8, NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4 hydrocarbyl; X1 is O, S or NRc and X2 is ═O, ═S or ═NRc; R7 is selected from hydrogen and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; R8 is selected from R7 and carbocyclic and heterocyclic groups having from 3 to 12 ring members; R9 is selected from R8, COR8 and SO2R8; or NR7R8 or NR7R9 may each form a heterocyclic group having from 5 to 12 ring members; but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and / or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

A radiation curable composition comprising a urethane oligomer with a polyester backbone which composition, when cured, has improved hydrolytic stability. The composition comprises a urethane oligomer, having a polyester backbone with a number average molecular weight of less than about 1000, wherein the polyester backbone is at least in part based on a diol component wherein at least one carbon at the beta -position with respect to a hydroxyl group bears two carbon-containing substituents having a total of at least three carbon atoms. Alternatively, when the composition comprises a urethane oligomer with a number average molecular weight of less than about 2000, having a polyester polyol backbone with a number average molecular weight of less than about 1000, the polyester backbone is at least in part based on a diol component wherein at least one carbon at the beta -position with respect to a hydroxyl group bears at least one carbon-containing substituent.

Simple, economical preparative processes for the provision of pure hydroxyl functional materials that are derived by converting the alkene groups of the unsaturated molecules found in vegetable oils, into hydroxyl groups.